Access
To read this story in full you will need to login or make a payment (see right).
insight
Nature 411, 380-384 (17 May 2001) | doi:10.1038/35077246
Open Innovation Challenges
-
Protect Enzyme from In Planta Degradation
A proposal for stable expression of an enzyme in corn seed is desired.
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
- More Challenges
- Powered by:
nature jobs
Scientist, Pathway Informatics
- Philip Morris International (PMI)
- Neuchâtel, Switzerland
Molecular Biology Team Leader
- AstraZeneca
- Alderley, Cheshire United Kingdom
progress Progress in human tumour immunology and immunotherapy
Steven A. Rosenberg1
Abstract
Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney cancer have shown that immunological manipulations can mediate the durable regression of metastatic cancer. The molecular identification of cancer antigens has opened new possibilities for the development of effective immunotherapies for patients with cancer. Clinical studies using immunization with peptides derived from cancer antigens have shown that high levels of lymphocytes with anti-tumour activity can be raised in cancer-bearing patients. Highly avid anti-tumour lymphocytes can be isolated from immunized patients and grown in vitro for use in cell-transfer therapies. Current studies are aimed at understanding the mechanisms that enable the cancer to escape from immune attack.
To read this story in full you will need to login or make a payment (see right).
